1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Krsnaa Diagnostics Limited

Krsnaa Diagnostics Limited

KRSNAA.NS
Krsnaa Diagnostics LimitedIN flagNational Stock Exchange of India
544.80
INR
-6.35
- -
17.67BMarket Cap
Krsnaa Diagnostics Limited
KRSNAA.NS
(National Stock Exchange of India)

Recent

price

544.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
66.64
82.31
126.27
152.44
155.15
195.18
222.15
238.47
238.69
Revenue per Share
-18.49
-35.66
58.9
22.89
19.78
17.9
24.04
31.3
31.33
Basic EPS, GAAP
-13.22
-12.4
11.38
-1.27
-20.72
-53.41
-12.17
-23.5
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
2.5
2.72
2.5
2.75
- -
Dividend per Share
-34.73
-70.39
-11.06
14.35
30.96
46.18
67.1
5
5.01
Book Value per Share
-32.1
-68
-3.74
228.3
234.38
254.32
272.54
301.04
301.32
Tangible Book Value per Share
31
31
31
30
31
32
32
32
32
Basic Weighted Avg Shares
2,092
2,584
3,965
4,554
4,871
6,196
7,172
7,728
7,728
Sales/Revenue/Turnover
15.43
11.77
14.35
19.83
14.21
11.26
14.2
15.71
15.71
Operating Margin (%)
256
323
374
414
538
745
883
905
905
Depreciation Expense
-581
-1,120
1,849
684
621
568
776
1,014
1,014
Net Income, GAAP
- -
- -
37.41
20.95
22.56
18.81
24.42
22.2
22.2
Effective Tax Rate (%)
-27.75
-43.32
46.65
15.02
12.75
9.17
10.82
13.13
13.13
Profit Margin (%)
153
328
643
2,131
1,237
1,397
1,091
4,631
4,631
Working Capital
921
1,227
1,680
331
243
419
472
4,683
4,683
LT Debt
-849
-1,970
2,319
6,844
7,387
8,098
8,828
9,804
9,804
Total Equity
- -
- -
14.59
12.1
7.21
6.55
7.51
7.26
7.26
Return on Invested Capital (%)
- -
- -
86.3
31.23
62.84
31.31
26.49
26.41
26.41
Return on Capital (%)
- -
- -
- -
- -
88.68
46.63
42.73
87.13
87.12
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
1,968
- -
660
LT Borrowings
538
- -
4,371
LT Finance Leases
351
- -
311
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
- -
32
Market Capitalization
24,478
23,330
16,845

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
5,767
- -
7,383
Cash, Cash Equivalents & STI
1,597
- -
3,920
Accounts Receivable, Net
3,583
- -
2,955
Inventories
315
- -
267
Total Current Liabilities
4,075
- -
2,752
Payables & Accruals
- -
- -
- -
ST Debt
1,968
- -
660
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
46.56%
11.06%
Free Cash Flow
- -
336.26%
93.79%
Net Income, GAAP
- -
-2.69%
30.7%
Sales/Revenue/Turnover
- -
14.5%
7.75%
Total Cash Common Dividend
- -
- -
10.52%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,396
1,554
1,583
1,663
6,196
2025
1,702
1,863
1,745
1,861
7,172
2026
1,930
2,060
1,812
1,926
7,728

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4.66
3.35
4.09
- -
17.9
2025
5.55
6.07
6.01
6.4
24.04
2026
6.35
7.38
4.72
12.86
31.3

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2.72
2025
- -
- -
- -
- -
2.5
2026
- -
- -
- -
- -
2.75
Similar Companies
Cordlife Group Limited (P8A.SI)
Medivolve Inc. (MEDVF)
BCAL Diagnostics Limited (BDX.AX)
Bio-Genex Laboratories, Inc. (BGNX)
Aeon Global Health Corp. (AGHC)
Vimta Labs Limited (VIMTALABS.NS)
Business
Krsnaa Diagnostics Limited operates as one of India's largest providers of technology-enabled diagnostic services, specializing in radiology, pathology, and teleradiology through public-private partnerships with government hospitals, medical colleges, and community health centers across semi-urban and rural areas. The company offers comprehensive radiology services via 148 centers equipped with CT scans, MRI machines, ultrasound, mammography, DEXA, and digital X-ray; teleradiology through India's first NABH-accredited hub with 1,443 tele-reporting centers; and pathology services encompassing 120 processing labs, 1,895 collection centers, and over 2,544 pathological tests including routine biochemistry, specialized molecular diagnostics, histopathology, flow cytometry, and genetics via NGS, supported by home collection, health packages for diabetes, cardiac, thyroid, and wellness screening, and advanced automation. Founded in 2010 and headquartered in Pune, Maharashtra, Krsnaa serves patients across 17 states and union territories spanning 150+ districts, with a network exceeding 3,600 centers and operations in both B2B (PPP contracts averaging 5-10+ years for pathology and 10+ years for radiology) and B2C segments including company-owned labs in major cities and franchise models. Recent developments include a 23.53% stake acquisition in Apulki Healthcare in 2024 to become the exclusive diagnostics partner for its cancer and cardiac hospitals over 30+ years; a strategic alliance with Medikabazaar and United Imaging investing over ₹300 crore to deploy 30+ advanced imaging centers in Tier-2/3 cities; expansion of 40 retail labs, 20 city scan centers, and 375 pathology collection centers in Q1 FY25 alongside new PPP projects in Maharashtra (17 MRI/CT), Rajasthan, Odisha, Assam, and Madhya Pradesh; and record H1 FY26 revenue growth of 12% with 19% net profit increase, driven by Rajasthan rollout and patient volume surges.